On 31 January 2008 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.
Under the programme Novo Nordisk will repurchase B shares for an amount of up to DKK 2 billion in the period from 31 January 2008 to 6 August 2008.
Since the announcement as of 17 March 2008, the following transactions have been made under the programme:
|
|
Number of shares |
Average purchase price |
Transaction value, DKK |
|
Accumulated, last announcement |
1,657,907 |
|
541,310,698 |
|
17 Mar 2008 |
50,000 |
317.7900 |
15,889,500 |
|
18 Mar 2008 |
50,000 |
320.9500 |
16,047,500 |
|
19 Mar 2008 |
50,000 |
323.4900 |
16,174,500 |
|
25 Mar 2008
26 Mar 2008
27 Mar 2008 |
50,000
50,000
50,000 |
326.1300
319.6500
318.0200 |
16,306,500
15,982,500
15,901,000 |
|
28 Mar 2008 |
50,000 |
315.6000 |
15,780,000 |
|
Accumulated, 2008 |
2,007,907 |
|
653,392,198 |
With the transactions stated above, Novo Nordisk owns a total of 26,968,090 treasury shares, corresponding to 4.2% of the share capital. The total amount of shares in the company is 646,960,000 including treasury shares.
Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 26,000 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.
Further information:
|
Media: |
Investors: |
|
|
|
|
Outside North America: |
Outside North America: |
|
Elin K Hansen |
Mads Veggerby Lausten |
|
Tel: (+45) 4442 3450 |
Tel: (+45) 4443 7919 |
|
|
|
|
|
Hans Rommer |
|
|
Tel: (+45) 4442 4765 |
|
|
|
|
|
|
|
In North America: |
In North America: |
|
Sean Clements |
Christian Qvist Frandsen |
|
Tel: (+1) 609 514 8316 |
Tel: (+1) 609 919 7937 |
Stock Exchange Announcement no 17 / 2008